Profile and Outcomes of Pediatric Hematology and Oncology Patients Diagnosed with COVID-19 in the Philippine General Hospital
DOI:
https://doi.org/10.47895/amp.v58i7.6865Keywords:
Abstract
Introduction. The coronavirus pandemic has affected millions worldwide. Better understanding of COVID-19 in
pediatric hematology-oncology patients in a resource-limited setting is crucial to improve care as the pandemic
ensues.
Objectives. This study describes the clinical profile and outcomes of pediatric hematology oncology patients with COVID-19 seen at the Philippine General Hospital (PGH).
Methods. A retrospective, descriptive review of pediatric hematology oncology patients with COVID-19 seen
between March 2020 to March 2021 in PGH was done.
Results. Forty patients were identified. Seventeen percent had non-malignant hematologic conditions, 40% had
leukemias, and 42.5% had solid tumors. Fever and cough were the most common manifestations. Seventy-six
percent were on treatment, 9% were newly diagnosed, and 7% were in relapse or disease progression. Fifty-five
percent had mild COVID-19; 5% and 2.5% had severe and critical COVID-19, respectively. Thirty-seven percent
were asymptomatic. Cancer-related therapy was placed on hold for most patients. There were two mortalities, none was due to COVID-19.
Conclusion. Results suggest that patients with hematologic and oncologic conditions have a mild course, with
majority showing recovery from COVID-19. Delays in cancer-related therapy however, may contribute to disease
progression and mortality.